Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers

Published:2019-06-01 Issue:6 Volume:5 Page:824
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Shroff Rachna T.¹,Javle Milind M.²,Xiao Lianchun³,Kaseb Ahmed O.²,Varadhachary Gauri R.²,Wolff Robert A.²,Raghav Kanwal P. S.²,Iwasaki Michiko²,Masci Peter⁴,Ramanathan Ramesh K.⁴,Ahn Daniel H.⁴,Bekaii-Saab Tanios S.⁴,Borad Mitesh J.⁴

Affiliation:

1. Division of Hematology/Oncology, Department of Medicine, University of Arizona Cancer Center, Tucson

2. Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston

3. Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston

4. Department of Medical Oncology, Mayo Clinic, Phoenix, Arizona

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

http:///jamaoncology/article-pdf/5/6/824/17667075/jamaoncology_shroff_2019_oi_190014.pdf

Reference22 articles.

1. Genetics of biliary tract cancers and emerging targeted therapies.;Hezel;J Clin Oncol,2010

2. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.;Valle;N Engl J Med,2010

3. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials.;Valle;Ann Oncol,2014

4. Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients.;Kim;Cancer Chemother Pharmacol,2017

5. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.;Von Hoff;J Clin Oncol,2011

Cited by 372 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cholangiocarcinoma;Treatment and Management of Tropical Liver Disease;2025

2. Hypocrellin A against intrahepatic Cholangiocarcinoma via multi-target inhibition of the PI3K-AKT-mTOR, MAPK, and STAT3 signaling pathways;Phytomedicine;2024-12

3. Safety of pressurized intraperitoneal aerosolized chemotherapy in biliary cancer patients with peritoneal metastases;Future Oncology;2024-09-12

4. Racial and Sex Differences in Genomic Profiling of Intrahepatic Cholangiocarcinoma;Annals of Surgical Oncology;2024-09-09

5. Chinese national clinical practice guideline on diagnosis and treatment of biliary tract cancers;Chinese Medical Journal;2024-09-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3